The leading research and development park at Colworth Park, Bedfordshire has secured a new tenant. MIP Diagnostics, a spin-out from the University of Leicester, are planning to upgrade from the university campus to the facilities that are on offer at Colworth Park in order to expand its team and continue their research into synthetic alternatives to antibodies. The business develops ‘nanostructured molecularly imprinted polymers’ (nanoMIPs), which can be used to replace antibodies in a wide range of applications, from vaccines, medical research and diagnostics to oil and gas, food and environmental testing.

MIP Diagnostics closed a £1.5m funding round supported by Mercia Fund Managers and a number of private investors. This new funding will enable MIP Diagnostics to expand its team, set up new production facilities and develop its own products to sell under licence.

They will soon be joining one of the 7 buildings at the 91 acre business park development, which is located on the Oxford to Cambridge arc, and is one of Unilever’s six global research and development sites.

To read more about MIP Diagnostic’s plans, click here: